Blog Viewer

STP Virtual Continuing Education Courses 💻 Approved for 4.00 RACE Credits ✔ — Register Today!

By Tierre Miller posted 06-28-2022 15:38

  

These programs have been approved for 4.00 hours of continuing education credit in jurisdictions that recognize RACE approval.


From Anticipated Immunomodulation to Safety Concern: Use of Immune Biomarkers in Preclinical Studies

Friday, August 12, 2022 |12:00 Noon–3:45 PM EDT

Co-Chairs: Caitlyn Carter, DVM, DACVP, Charles River Laboratories; and Michael Logan, DVM, PhD, DACVP, AbbVie

Biomarkers of the immune system are being applied to preclinical safety studies with increasing frequency as the availability of method and platform options continues to expand. This course will focus on the use of traditional and novel biomarkers of the immune system that are being used on preclinical safety studies. Practical considerations for their appropriate, and sometimes inappropriate use will be presented including biomarker selection, application in various preclinical settings, study design, sampling collection optimization (matrix, kinetics, timing and collection), and interpretative considerations. Method limitations, pitfalls to avoid, and successful implantation strategies will also be discussed with supporting case examples. Finally, topics related to immunology biomarker components specific to emerging novel therapeutic platforms (e.g., CD3 engagement, bispecific antibodies, cell and gene therapies) will be presented.

Overview and Considerations for the Use of Biomarkers of the Immune System in Preclinical Safety Studies
Adam Aulbach, DVM, DACVP, Inotiv

Getting It Right: The Correct Assays, Matrices, and Intervals Result in a Robust Data Set. Now…How Do We Interpret Them?
Erin Vaughn, PhD, AbbVie

Possible vs. Advisable: How Do We Optimally Use (and Not Abuse) Immunology Biomarkers in a Preclinical Setting?
Rob Caldwell, PhD, AbbVie

Platform Specific Considerations: What Biomarkers Provide the Best Value for My Specialized Target/Mechanism/Modality?
Danice Wilkins, PhD, MS, Charles River Laboratories




0 comments
21 views

Permalink